4baseCare launches Indian population specific cancer gene panel

Precision oncology company, 4baseCare launched a population-specific tumour gene panel called TARGT Indiegene on Monday.

The panel has been derived from whole exome and whole transcriptome data of over 1500 cancer patients across 28 different cancer types. Most of the patients were presented with stage III/ IV disease, and presented with disease progression and had exhausted all the options in the standard of care, said the company release.

According to the company, the TARGT Indiegene cancer panel is based on insights generated from tumour tissues of Indian cancer patients resulting in better success rates using precision medicine in the management of cancer.

Commenting on the occasion, Hitesh Goswami, CEO, 4baseCare, said, “Our vision is to leverage technology to develop affordable solutions to personalise patient care in oncology. With TarGT Indiegene, we want to deliver the promise of precision to help personalise the treatment for Indian cancer patients…

Read More